The Role of Immunotherapy in Radiation Oncology

Narra Kumar^*
*Correspondence: Narra Kumar, Department of Radiation Oncology, Rutgers Cancer Institute, NJ 08901, USA, Email:

Introduction

Immunotherapy has emerged as a revolutionary treatment modality in oncology, reshaping the landscape of cancer therapy and offering new hope to patients. Within radiation oncology, immunotherapy is garnering significant attention as a powerful adjunct to traditional radiotherapy. The combination of these two approaches promises to enhance treatment efficacy, overcome resistance, and potentially achieve better long-term survival outcomes for patients with various types of cancer. This manuscript explores the role of immunotherapy in radiation oncology, addressing the biological mechanisms that link these two treatment modalities, the current state of clinical research, the challenges faced, and the future potential of this approach.

Description

The concept of immunotherapy in cancer treatment revolves around harnessing the body’s immune system to target and destroy cancer cells. Immunotherapy can be broadly classified into several categories, including immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and adoptive cell therapies. The key to immunotherapy’s success lies in its ability to specifically target cancer cells while sparing normal tissues, leading to less toxicity compared to conventional therapies such as chemotherapy and radiation. Immunotherapy can induce a lasting immune response, offering the potential for long-term control or even eradication of cancer. However, not all cancers respond to immunotherapy, and its effectiveness can vary based on factors such as the tumor microenvironment, the immune landscape of the patient, and the type of cancer being treated [1].

Radiotherapy, on the other hand, remains a cornerstone of cancer treatment, commonly used to treat localized tumors or shrink tumors before surgical removal. The process of radiotherapy involves the use of ionizing radiation to damage the DNA of cancer cells, leading to their death. One of the key challenges in radiation oncology is the fact that tumors can develop resistance to radiation over time, limiting the effectiveness of this treatment. Furthermore, radiotherapy can lead to substantial toxicity in normal tissues surrounding the tumor, which can complicate the management of cancer and reduce the overall quality of life for patients. The combination of immunotherapy and radiation therapy is based on the understanding that radiation can have immunomodulators effects. When radiation is delivered to a tumor, it not only directly damages the DNA of cancer cells but also generates an array of molecular signals that can influence the immune system. Radiation can lead to the release of tumor antigens, which are molecules that can be recognized by the immune system as foreign [2,3].

This process can activate an immune response, triggering the recognition of the tumor by immune cells such as T lymphocytes. Radiation also alters the tumor microenvironment, potentially making it more conducive to immune cell infiltration and activation. These immunological effects of radiation can enhance the effectiveness of immune checkpoint inhibitors and other forms of immunotherapy. One of the key mechanisms by which immunotherapy enhances the efficacy of radiation therapy is through the concept of “abscopal effects.” The abscopal effect refers to the phenomenon whereby radiation treatment directed at a localized tumor can lead to the shrinkage or eradication of distant, non-irradiated tumors. This occurs because the immune system, activated by the localized radiation, can recognize and attack tumor cells at sites distant from the original irradiated tumor. When combined with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 antibodies, which work by blocking the immune checkpoint proteins that suppress immune responses, the immune system can be further unleashed to target tumor cells both at the site of radiation and throughout the body [4,5].

Clinical studies investigating the combination of immunotherapy and radiation have shown promising results in various cancers, including melanoma, Non-Small Cell Lung Cancer (NSCLC), and head and neck cancers. In melanoma, for instance, the combination of radiation therapy and immune checkpoint inhibitors has been associated with improved progressionfree survival and overall survival in patients. In NSCLC, the use of immune checkpoint inhibitors in combination with radiation has demonstrated the ability to overcome resistance to radiation and improve response rates, even in patients who previously did not respond to either therapy alone. These findings highlight the synergistic potential of combining radiation and immunotherapy. Despite the promising results, several challenges remain in optimizing the combination of immunotherapy and radiation. One of the main obstacles understands how to effectively integrate these treatments in a way that maximizes their benefits while minimizing toxicities.

Conclusion

In conclusion, the integration of immunotherapy into radiation oncology represents a promising frontier in cancer treatment. By harnessing the power of the immune system, immunotherapy has the potential to overcome some of the limitations of traditional radiation therapy, including tumor resistance and toxicity to normal tissues. The combination of these two modalities can lead to enhanced antitumor immunity, offering the potential for better clinical outcomes in a variety of cancers. While challenges remain in optimizing treatment regimens, overcoming immune suppression, and managing toxicities, ongoing research is providing valuable insights into how best to harness the synergistic potential of radiation and immunotherapy. As our understanding of the immune system and tumor biology continues to evolve, the future of radiation oncology is likely to be increasingly intertwined with the promise of immunotherapy, offering patients new opportunities for more effective and personalized cancer treatment.

Acknowledgment

None.

Conflict of Interest

No potential conflict of interest was reported by the authors.

References

1. Kratzer, Tyler B., Priti Bandi, Neal D. Freedman and Robert A. Smith, et al. "Lung cancer statistics, 2023." Cancer 130 (2024): 1330-1348.

Google Scholar, Crossref, Indexed at

2. Etienne, Harry, Bianca Battilana, Jonathan Spicer and Raphael S. Werner, et al. "Defining resectability: When do you try to take it out?." JTCVS Open (2024).

Google Scholar, Crossref, Indexed at

3. Dillman, Robert O., James Herndon, Stephen L. Seagren and Walter L. Eaton Jr, et al. "Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial." J Natl Cancer Inst 88 (1996): 1210-1215.

Google Scholar, Crossref, Indexed at

4. Qu, Jialin, Li Wang, Man Jiang and Deze Zhao, et al. "A review about pembrolizumab in first-line treatment of advanced NSCLC: Focus on KEYNOTE studies." Cancer Manag Res (2020): 6493-6509.

Google Scholar, Crossref, Indexed at

5. Cron, Kyle R., Kaya Zhu, Deepa S. Kushwaha and Grace Hsieh, et al. "Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer." PLoS One 8 (2013): e73710.

Google Scholar, Crossref, Indexed at